Pozen shares jump after FDA filings for cardio drugs; RXi finds $26M for RNA drug research;

 @FierceBiotech: Guest post by Lee Feigenbaum on FierceBiotechIT.com: Big Data sheds light on pharma's 'Small Data' problems. Industry Voices | Follow @FierceBiotech

 @JohnCFierce: Blessed by Gates, crowdfunding site funnels cash for high-risk R&D. Report | Follow @JohnCFierce

 @RyanMFierce: Aastrom sinks after biotech flushes PhIII study for cardio therapy, halves staff. News | Follow @RyanMFierce

> Melbourne, Australia-based Prana Biotechnology ($PRAN) has found A$7 million through a stock offering with plans to speed mid-stage development of its lead drug PBT2 for treating Huntington's and Alzheimer's diseases. Item

> Pozen ($POZN) shares jumped on news that the company has filed for FDA approval of the two related drug candidates PA32540 and PA8140 for preventing cardiovascular disease. Article

> RXi Pharma has found $26 million from investors as the biotech pursues development of RNA therapies. Report

Medical Device News

 @FierceMedDev: Next-gen prostate cancer Dx faces skepticism, competition. Story | Follow @FierceMedDev

 @MarkHFierce: Some companies are shedding drug operations to focus more on devices, while BD is adding a (generic) drug arm. Press release | Follow @MarkHFierce

 @DamianFierce: Intuitive Surgical will have its day in court after a judge ruled to allow a patient's suit. News | Follow @DamianFierce

> As sale rumors abound, Life Tech expands in China. More

> Quidel gains CE mark for herpes/chicken pox molecular Dx. Story

> Becton Dickinson jumps into generic drug business. Article

Pharma News

@FiercePharma: Pfizer's targeted lung cancer drug Xalkori too expensive, U.K. cost-effectiveness body says. More | Follow @FiercePharma

@EricPFierce: Teva, Samsung face biosimilar realities. The business is not for the "faint of heart," but has great potential. More | Follow @EricPFierce

> Can public health campaigns goose Gardasil and Cervarix sales? More

> NICE nixes Pfizer's targeted lung cancer drug as too pricey. Article

> Novartis sweats Glivec patent verdict in India. Report

Drug Delivery News

@MichaelGFierce: FierceDrugDelivery Special Report: Drug-Delivery Device Combos to Watch. Report | Follow @MichaelGFierce

> FDA approves Novartis' inhaled powder drug for cystic fibrosis infection. Story

> Intarcia enrolls PhIII glucose control study for Type 2 diabetes. Item

> Nanoparticles deliver cancer drug, spare fertility. News

> FDA panel OKs Titan's addiction drug delivery platform. More

And Finally… Fight cancer with Big Data? ASCO has mounted a major project to build a large database that would enable oncologists to hunt down optimal cancer treatments with the ease of doing a Google search. Article

Suggested Articles

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets.